PMID- 37709824
OWN - NLM
STAT- MEDLINE
DCOM- 20230918
LR  - 20231121
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Sep 14
TI  - The efficacy and safety of anamorelin for patients with cancer-related 
      anorexia/cachexia syndrome: a systematic review and meta-analysis.
PG  - 15257
LID - 10.1038/s41598-023-42446-x [doi]
LID - 15257
AB  - Cancer-related anorexia/cachexia syndrome (CACS) is characterized by anorexia and 
      loss of body weight. Evidence is insufficient to strongly endorse any 
      pharmacologic agent for the treatment of CACS. In this systematic review, we 
      assessed the efficacy of oral anamorelin treatment for patients with CACS. On 
      July 6, 2022, we systematically searched the following databases for randomized 
      controlled trials (RCTs) of adults with CACS comparing oral anamorelin versus 
      placebo: CENTRAL, PubMed, EMBASE, and ICHUSHI. The primary outcomes were total 
      body weight (TBW), patient-reported quality of life (QOL), and adverse events 
      (AEs). Secondary outcomes included lean body mass (LBM), overall survival (OS), 
      non-dominant hand grip strength (HGS), and appetite. We included seven RCTs with 
      a total of 1944 CACS patients. Anamorelin significantly increased TBW (mean 
      difference (MD) 1.73, 95% confidence interval (CI) 1.34-2.13, p < 0.00001), LBM 
      (MD 1.06, 95% CI 0.30-1.81, p = 0.006), and QOL (standardized mean difference 
      (SMD) 0.16, 95% CI 0.04-0.27, p = 0.006) compared with placebo without a 
      significant difference in all AEs, severe AEs, OS, HGS or appetite. Anamorelin 
      may be an effective treatment for CACS patients; however, further studies are 
      needed to confirm the efficacy and safety of this drug.
CI  - (c) 2023. Springer Nature Limited.
FAU - Taniguchi, Jumpei
AU  - Taniguchi J
AD  - Graduate School of Public Health, St. Luke's International University, Tokyo, 
      Japan.
FAU - Mikura, Sunao
AU  - Mikura S
AD  - Graduate School of Public Health, St. Luke's International University, Tokyo, 
      Japan.
FAU - da Silva Lopes, Katharina
AU  - da Silva Lopes K
AD  - Graduate School of Public Health, St. Luke's International University, Tokyo, 
      Japan. lopes@slcn.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230914
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - DD5RBA1NKF (anamorelin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Anorexia/drug therapy/etiology
MH  - Cachexia/drug therapy/etiology
MH  - *Neoplasms/complications
MH  - Administration, Oral
PMC - PMC10502008
COIS- The authors declare no competing interests.
EDAT- 2023/09/15 00:42
MHDA- 2023/09/18 12:43
PMCR- 2023/09/14
CRDT- 2023/09/14 23:21
PHST- 2023/04/19 00:00 [received]
PHST- 2023/09/10 00:00 [accepted]
PHST- 2023/09/18 12:43 [medline]
PHST- 2023/09/15 00:42 [pubmed]
PHST- 2023/09/14 23:21 [entrez]
PHST- 2023/09/14 00:00 [pmc-release]
AID - 10.1038/s41598-023-42446-x [pii]
AID - 42446 [pii]
AID - 10.1038/s41598-023-42446-x [doi]
PST - epublish
SO  - Sci Rep. 2023 Sep 14;13(1):15257. doi: 10.1038/s41598-023-42446-x.